Issue #6 2017 – Digital Version

Posted: 14 December 2017 | | No comments yet

This issue celebrates European Pharmaceutical Review’s 21st birthday through 21 interviews with leading lights from across the pharmaceutical industry…

  • FOREWORD: Objectionable organisms in non-sterile medicinal products
    Dave Elder, David P Elder Consultancy
  • REGULATORY INSIGHT: Obstacles to success for biosimilars in the US market
    Sarfaraz K Niazi, Karyo Biologics
  • MICROBIOLOGY: A comprehensive review of the revised European Pharmacopoeia Chapter 5.1.6 (part two)
    Michael J Miller, Microbiology Consultants and
  • IN-DEPTH FOCUS: Formulation, Development & Delivery
    Darren Whitaker and Chris Edlin, Pharmaceutical Manufacturing Technology Centre
  • IN-DEPTH FOCUS: Biopharmaceutical Development & Processing
  • PARTICLE SIZING: The importance of particle size analysis
    Dave Elder, David P Elder Consultancy; Stephen Tindal, Peter Nelson and Gene Pacowski, Catalent Pharma Solutions
  • 21st ANNIVERSARY SUPPLEMENT: 21 interviews with key opinion leaders to celebrate 21 years of European Pharmaceutical Review

The digital issue of Issue #6 2017 is restricted - login or subscribe free to access

EPR Issue 1 2024Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here